Colistin, also known as polymyxin E, is a cyclic polypeptide antibiotic that is currently used as a last-line treatment in clinical settings. Its primary mode of administration is intravenous injection, and it exhibits strong antibacterial effects against Salmonella spp., Pseudomonas aeruginosa, and Escherichia coli. However, its disadvantages include significant nephrotoxicity and neurotoxicity, requiring careful consideration of dosage and administration intervals in clinical use. Due to these factors, administering a dosage that is too low may fail to completely eradicate bacteria in the initial treatment phase, leading to reduced subsequent antibacterial efficacy. Conversely, administering doses that are too high or too frequent significantly increases the risk of nephrotoxic and neurotoxic reactions in patients.
Using patented chelated composite micelle technology, colistin is encapsulated to form colistin composite micelles. In pharmacokinetic tests on rodents, this formulation has demonstrated advantages such as increased safety. Consequently, it is expected that the effective dosage and dosing frequency required for clinical use will decrease. Moreover, for patients with moderate to severe infections, this treatment may reduce toxicity while enhancing therapeutic efficacy.
Enhanced safety: Compared to free colistin, CCM-CL has a higher safe dosage, reducing toxicity and side effects.
Improved drug delivery: CCM-CL enables targeted drug delivery, allowing the medication to more efficiently reach the infection site while minimizing systemic side effects
Extended duration of efficacy: CCM-CL prolongs the drug's half-life, enabling sustained release within the body for longer-lasting treatment.
Increased drug bioavailability: The area under the curve (AUC) of CCM-CL is higher than that of free colistin, indicating that the drug has greater absorption and a longer duration in the body.
Higher patient survival rate: Compared to free colistin, CCM-CL can effectively enhance therapeutic efficacy, reduce mortality risk, and increase patient survival rates.
